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Immunologically, active visceral leishmaniasis (VL) is characterized by profound immu-
nosuppression, severe systemic inflammatory responses, and an impaired capacity to 
control parasite replication. Neutrophils are highly versatile cells, which play a crucial 
role in the induction as well as the resolution of inflammation, the control of pathogen 
replication, and the regulation of immune responses. Neutrophil functions have been 
investigated in human cutaneous leishmaniasis; however, their role in human VL is 
poorly understood. In the present study we evaluated the activation status and effector 
functions of neutrophils in patients with active VL and after successful anti-leishmanial 
treatment. Our results show that neutrophils are highly activated and have degranulated; 
high levels of arginase, myeloperoxidase, and elastase, all contained in neutrophils’ 
granules, were found in the plasma of VL patients. In addition, we show that a large 
proportion of these cells are immature. We also analyzed effector functions of neutrophils 
that are essential for pathogen clearance and show that neutrophils have an impaired 
capacity to release neutrophil extracellular traps, produce reactive oxygen species, and 
phagocytose bacterial particles, but not Leishmania parasites. Our results suggest that 
impaired effector functions, increased activation, and immaturity of neutrophils play a key 
role in the pathogenesis of VL.
Keywords: visceral leishmaniasis, neutrophils, neutrophil extracellular traps, reactive oxygen species, 
phagocytosis
2Yizengaw et al. Neutrophils during Human Visceral Leishmaniasis
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 517
inTrODUcTiOn
Leishmaniases are caused by a group of vector-borne parasites 
that represent a major public health problem worldwide, affect-
ing 98 countries (1). The diseases present with a wide range of 
symptoms, ranging from cutaneous leishmaniasis (CL) to the 
most severe form of the disease, visceral leishmaniasis (VL). An 
estimated 0.2–0.4 million new cases of VL and 50,000 deaths 
occur each year; however, due to vast under-reporting of cases, 
these numbers are likely to be a significant underestimation 
of the real burden (1, 2). The majority of VL cases occur in 
Bangladesh, India, Nepal, South Sudan, Sudan, Ethiopia, and 
Brazil (2). VL is caused by Leishmania donovani or Leishmania 
infantum parasites that are transmitted during the blood meal 
of infected sand flies, and migrate from the skin to internal 
organs such as spleen, liver, and bone marrow. The majority of 
individuals infected with these parasites will be able to control 
infection; however, some will develop symptomatic disease, in 
which the mortality rate can be as high as 100% in untreated 
patients. The symptoms include fever, weight loss, severe ane-
mia, hepato- and splenomegaly, and pancytopenia. However, 
the factors accounting for the development of symptomatic 
disease or control of VL are poorly understood. It is generally 
accepted that active VL is associated with strong immune sup-
pression, as shown by the impaired capacity of peripheral blood 
mononuclear cells (PBMCs) to proliferate and produce IFN-γ 
[reviewed in Ref. (3, 4)]. Recently, this notion was challenged 
by studies performed in India (5, 6): using a whole blood assay, 
the authors showed that CD4+ T cells produce similar levels 
of IFN-γ that can limit Leishmania parasite replication during 
active VL. In contrast, our recent work performed in Ethiopia 
showed that whole blood cells produce no or low IFN-γ, sug-
gesting that whole blood cells from VL patients in Ethiopia are 
hyporesponsive (7).
One key feature of patients with active VL is the high plasma 
level of pro-inflammatory cytokines and chemokines such as 
TNF-α, IFN-γ, IL-1, IL-6, IL-8, IL-12, and IP-10 [reviewed in 
Ref. (3, 4)]; all characteristic of a systemic and acute inflam-
matory response, similar to that observed in diseases such as 
severe malaria and sepsis (8, 9). Neutrophils are one of the main 
mediators of inflammation, they are the first cells to be recruited 
to the site of inflammation and can eliminate pathogens via 
several mechanisms; including phagocytosis, production of 
toxic molecules such as reactive oxygen species (ROS), anti-
bacterial proteins, and neutrophil extracellular traps (NETs), 
that function by killing and/or containing pathogens (10, 11). 
They also play a crucial role in the resolution of inflammation by 
scavenging cytokines, producing  pro-resolving mediators and 
undergoing apoptosis (10, 11). However, the serine proteases 
contained in the granules of neutrophils can also cause exces-
sive tissue damage [reviewed in Ref. (12)]. Neutrophil function 
in human CL has been investigated in several studies (13–15) 
and they indicate that neutrophils are active players in patients 
with both acute and chronic CL and are important immune 
regulators that can have beneficial as well as detrimental effects 
(16). Since different Leishmania species can drive distinct 
neutrophil functions (17), it is of utmost importance that the 
phenotypes and functions of neutrophils isolated from patients 
infected by different Leishmania species are investigated. In 
VL patients, several studies have pointed to a possible role of 
inflammation in the pathogenesis of VL (18, 19); however, the 
role of neutrophils in human VL is poorly understood. Previous 
studies have shown that neutrophils from healthy donors 
have the ability to phagocytose and kill L. donovani (20). The 
killing mechanisms of intracellular Leishmania parasites in 
human neutrophils have not been fully identified; L. donovani 
phosphatase can suppress superoxide anion production, sug-
gesting that this might impair the ability of neutrophils to kill 
parasites (21). In addition, Leishmania-containing phagosomes 
in neutrophils avoid fusion with granules involved in acidifi-
cation of vacuoles, thereby contributing to parasite survival 
(22). L. donovani (23) and L. infantum (24) both can induce 
the release of NETs; however the survival of L. donovani was 
not compromised (23), whereas L. infantum was being killed 
at least in part via the activity of 3'-nucleotidase/nuclease (24). 
VL patients are severely neutropenic, and indeed, bacterial 
infections are common in these patients and are the primary 
cause of deaths (25). The severe neutropenia associated with 
VL has been shown to be reversed by GM-CSF, which resulted 
in reduced secondary infections, further emphasizing the role 
of neutrophils during VL (26).
In the present study, we characterized the activation status and 
effector functions of neutrophils during active VL and following 
successful treatment.
MaTerials anD MeThODs
subjects and sample collection
The study was approved by the Institutional Review Board of the 
University of Gondar (IRB, reference SBMLS/Dec. 199/07). For 
this cross-sectional study, non-endemic male controls with no 
prior history of VL were recruited amongst the hospital staff; male 
VL patients were recruited from the Leishmaniasis Treatment 
and Research Center of the Gondar University Hospital before 
and after treatment. Informed written consent was obtained 
from each patient and control. The exclusion criteria were age 
(<18 years) and coinfection with tuberculosis, malaria, and HIV. 
The diagnosis of VL was based on positive serology (rK39) and the 
presence of amastigotes in spleen or bone marrow aspirates (27). 
Patients were treated with a combination of sodium stibogluco-
nate (SSG, 20 mg/kg body weight/day) and paromomycin (PM, 
15 mg/kg body weight/day) injections, given intramuscularly for 
17 days or with Ambisome® (max of 30 mg/kg body weight, with 
six injections of 5 mg/kg body weight/day). There was an initial 
clinical cure (ICC) rate of 100% after treatment; ICC was defined 
as follows: at the end of treatment, patients look improved, afe-
brile, and have a smaller spleen size than on admission and have 
an increased hemoglobin (Hgb) level.
Six milliliter of blood was collected in heparin tubes and 
was processed within 10 min after collection: following density 
gradient centrifugation on HistopaqueH-1077 (Sigma), the 
plasma was isolated from the top layer and neutrophils from the 
erythrocyte fraction by dextran sulfate sedimentation (28), and 
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were used immediately. The blood from all three groups (healthy 
controls, VL patients and treated patients) was treated in the same 
way and within a maximum period of time of 2.5 h from the time 
the individuals were bled to the time samples were run on the 
flow cytometer.
It was sometimes difficult to obtain samples from all patients, 
for two main reasons: poor medical conditions of the patients at 
arrival in the hospital and/or frequent electricity cuts that did not 
allow for immediate processing of the blood. In addition, due to 
the severe pancytopenia of VL patients, and the small amount of 
cells recovered, it was not always possible to do all tests.
Leishmania donovani Parasites
GFP-labeled L. donovani (Dr. V. Yardley, LSHTM) was used for 
the phagocytosis assays and L. donovani isolated from a spleen 
biopsy obtained from a patient with active VL was used to deter-
mine parasite-induced production of ROS. The species of the 
GFP-labeled Leishmania strain was confirmed to be L. donovani 
by means of heat-shock protein 70 gene sequence analysis (29).
Flow cytometry
Characterization of Neutrophil Activation
The following antibodies were used to assess the activation status 
of neutrophils by flow cytometry: anti-CD10 (clone eBioSN5c), 
anti-CD11b (clone ICRF44), anti-CD13 (clone WM-15), anti-
CD15 (clone HI98), anti-CD16 (clone eBioCB16), anti-CD33 
(clone WM53), anti-CD62L (clone DREG-56), anti-CD66b (clone 
G10F5) (eBioscience), and anti-arginase I [HyCult Biotechnology: 
clone 6G3, labeled as described in Ref. (30)]. Cells were incubated 
with antibody concentration determined in preliminary experi-
ments, washed with PBS, the fixation step was performed with 
2% formaldehyde in PBS and the permeabilization step with 0.5% 
saponin in PBS. Median Fluorescence Intensity (MFI) was used 
to demonstrate increase or decrease in expression of the markers. 
The percentages for the isotype controls were <1%. At least 2,500 
CD15+ cells were collected for each sample.
Phagocytosis
Uptake of pHrodo® Green Escherichia coli BioParticles® Conjugate 
(Molecular probes™) was used to assess the phagocytic capacity 
of neutrophils, as described in the manufacturer’s protocol.
Uptake of parasites was assessed using GFP-labeled L. dono-
vani: the parasites were first incubated for 15 min in decomple-
mented human plasma; next, 1 × 105 neutrophils were cocultured 
with 5 × 106 GFP-labeled L. donovani at 37°C with 5% CO2. After 
60 min, neutrophils were washed twice in PBS. Trypan blue was 
added just before flow cytometry analyses to quench the fluores-
cence of non-internalized parasites (31).
rOs Production
Total ROS detection kit (Enzo) was used to evaluate the produc-
tion of ROS by neutrophils, as described in the manufacturer’s 
protocol.
Flow cytometry acquisition was performed using a 
FACSCalibur (BD Biosciences) and data were analyzed using 
Summit v4.3 software.
Total, Band, and segmented neutrophil 
counts
Total neutrophil counts were obtained using a CELL-DYN 1800 
(Abbott). Smears of purified neutrophils were stained with 
Giemsa and the percentages of band and segmented neutrophils 
per 100 neutrophils were counted microscopically.
elisa
IL-17A and IL-27 were measured in plasma with Ready-SET-Go! 
ELISA kits (eBioscience). Myeloperoxidase and elastase levels in 
plasma were measured using ELISA kits (BioVendor R&D). The 
ability of neutrophils to release NETs was assessed by measuring 
the NET-associated elastase using NETosis assay kit (Cayman 
Chemical). All ELISA were performed according to the manu-
facturers’ protocol.
arginase activity
The enzymatic activity of arginase was measured as previously 
described (32). To determine arginase activity in the plasma, urea 
concentrations were first determined in the plasma, without the 
activation and hydrolysis steps; these values were subtracted from 
those obtained by measuring the urea.
One unit of enzyme activity is defined as the amount of enzyme 
that catalyzes the formation of 1 mmol of urea per minute.
statistical analysis
Data were evaluated for statistical differences using a Wilcoxon 
matched-pairs tests or Kruskal–Wallis test (GraphPad Prism 
6) and differences were considered statistically significant at 
p <  0.05. Unless otherwise specified, results are expressed as 
median.
resUlTs
characterization of neutrophils  
in Patients with active Vl
Neutrophils are major players in the induction, maintenance, and 
resolution of inflammation (11). However, the role of neutrophils 
in active VL, a disease characterized by high systemic inflam-
mation, is poorly understood. Neutrophils were purified by 
dextran sulfate sedimentation (>95% of the cells in the live gate, 
Figure 1A) and the purity of neutrophils (defined as CD15+) was 
>99%, Figure 1B. We analyzed the activation status of neutro-
phils by measuring the levels of intracellular and surface markers 
of neutrophils that had been previously associated with activation 
(33). As shown in Figure 1, the MFIs of CD15 were significantly 
increased in VL patients (p =  0.0022) and in treated patients 
(p = 0.0122), as compared to controls. CD63 was also increased 
in VL patients (p =  0.0050) and decreased significantly after 
treatment (p = 0.0063). The MFI of intracellular arginase and the 
MFI of CD62L and CD10 were all decreased in neutrophils from 
VL patients (Figure 1, p = 0.0028, p = 0.0037, and p = 0.0007, 
respectively); whereas the MFIs of arginase and CD62L did not 
increase significantly (p >  0.05) following successful treatment 
of VL patients, CD10 expression was significantly increased 
A B
C D
E F v
FigUre 1 | activation status of neutrophils. (a) Neutrophils were isolated by dextran sulfate sedimentation from the blood of controls, VL, and treated patients 
(=VL patients after successful treatment, with initial clinical cure) and (B) the frequencies of CD15+ cells were determined by flow cytometry. The expression levels 
(MFI = Median Fluorescence Intensity) of CD15 [(c), 15 individuals in each group], CD63 [(D), 11 individuals in each group], arginase [(e), 11 individuals in each 
group], CD62L [(F), 15 individuals in each group], and CD10 [(g), 10 controls, 11 VL, and 10 treated patients] were determined in the cells from gate R4 by flow 
cytometry. Statistical differences were determined using a Kruskal–Wallis test.
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(p = 0.0006). No significant differences were found in the MFIs 
of CD13, CD16, CD33, and CD66b (data not illustrated).
The results presented in Figure 1 show that neutrophils are 
significantly more activated in VL patients.
Maturation stage of neutrophils
Since CD10 is present on immature band neutrophils (34), we 
estimated the maturation stage of neutrophils. Smears of purified 
neutrophils from controls, VL, and treated patients were stained 
with Giemsa and the numbers of segmented (Figure  2B) and 
band (Figure  2C) neutrophils were counted. Results presented 
in Figure  2A show that the frequency of band neutrophils is 
significantly higher in VL patients than in controls (p < 0.0001), 
and this did not change significantly after treatment. These results 
show that a large proportion of the neutrophils in the blood of VL 
patients are immature cells.
inflammatory cytokine Profile and 
evaluation of secreted granule content of 
neutrophils
IL-17A is associated with neutrophilic inflammation and indeed, 
our results show that IL-17A is significantly increased in the 
plasma of VL patients (Figure  3A, p <  0.0001). Since a recent 
study suggested that, in an experimental model of VL, IL-27 
mediates susceptibility to VL by suppressing IL-17, we measured 
the levels of IL-27 in the plasma of our three cohorts of individu-
als. As shown in Figure 3B, the levels of IL-27 were significantly 
increased in VL patients (p < 0.0001).
Arginase, myeloperoxidase, and elastase are present in 
primary granules of neutrophils, and are the last granules to be 
released upon activation of neutrophils. To further characterize 
the activation status of neutrophils, the levels of arginase, myelop-
eroxidase, and elastase were measured in the plasma of controls, 
AB C
FigUre 2 | Percentages of band neutrophils. Smears from PBMCs and 
neutrophils purified from the blood of 13 controls, 11 VL, and 10 treated 
patients (=VL patients after successful treatment, with initial clinical cure) by 
double density gradient centrifugation were stained with Giemsa and the 
percentages of segmented (B) and band (a,c) neutrophils were counted per 
50 neutrophils. Statistical differences were determined using a Kruskal–Wallis 
test.
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VL, and treated patients. Arginase activities, myeloperoxidase, 
and elastase levels were all significantly increased in plasma 
from VL patients (Figure 3C, p = 0.0024; Figure 3D, p < 0.0001; 
and Figure 3E, p < 0.0001, respectively); the levels of arginase, 
myeloperoxidase, and elastase decreased significantly after anti-
leishmanial treatment (Figure 3A, p = 0.0392, p < 0.0001, and 
p = 0.0093, respectively).
To determine whether these elevated levels of arginase, MPO, 
and elastase might be due to increased neutrophil counts in VL 
patients, the absolute neutrophil counts were measured and 
as shown in Figure  3F, it was strikingly lower in VL patients 
(p < 0.0001) and increased significantly (p = 0.0159) after suc-
cessful treatment, while still staying significantly lower than those 
from controls (p = 0.0034).
These results show that levels of arginase, MPO, and elastase 
are elevated in the plasma of VL patients and further confirm that 
VL patients are highly neutropenic.
effector Functions of neutrophils
Neutrophils play a major role in controlling pathogens by releas-
ing NETs, acting as phagocytic cells, and producing ROS (11). 
Next we assessed these effector functions in neutrophils isolated 
from controls, VL, and treated patients. Neutrophils were puri-
fied by dextran sulfate sedimentation (>95% of the cells in the 
live gate, Figure 1A). We analyzed the following neutrophil (as 
defined by CD15+ cells, >99%, Figure 1B) effector functions.
neTosis
Purified neutrophils were induced to release NETs by PMA and 
as shown in Figure  4, neutrophils from VL patients have an 
impaired capacity to undergo NETosis as compared to controls 
(p = 0.0399); this was maintained even after successful treatment.
Phagocytosis
Next, we assessed the capacity of neutrophils isolated from 
controls, VL, and treated patients to phagocytose particles and 
GFP-labeled L. donovani. Our results show that a significantly 
lower percentage of neutrophils (Figure  5A) isolated from VL 
patients phagocytosed significantly less particles (Figure  5B, 
p < 0.0001) as compared to controls; this was not significantly 
higher following successful treatment.
Next, the capacity of neutrophils to phagocytose GFP-labeled 
L. donovani parasites was assessed. As shown in Figures 5C,D, a 
similar percentages of neutrophils (Figure 5C) phagocytosed a 
similar number of parasites (Figure 5D).
These results show that neutrophils isolated from VL patients 
have an impaired capacity to phagocytose E. coli particles, but not 
L. donovani parasites.
rOs Production
Results in Figure 6 show that neutrophils from controls, VL, and 
treated patients produced increased levels of ROS following acti-
vation with pyocyanin (Figures 6A–C, p > 0.0001, p = 0.0078, 
p  =  0.0039, respectively); however, as shown in Figure  6D, 
increase in ROS production in response to pyocyanin was signifi-
cantly lower in VL patients (p = 0.0424) as compared to controls 
and this did not increase in treated patients (p > 0.05).
Next we measured the production of ROS following infec-
tion of neutrophils with L. donovani parasites. As shown in 
Figures  7A–C, L. donovani infection induced an increase in 
ROS production in the neutrophils isolated from all three groups 
(p = 0.0156); however, this increase was significantly lower in VL 
patients (Figure 7D, p = 0.0161); this improved after successful 
treatment (Figure 7D, p = 0.0161).
These results show that neutrophils isolated from VL patients 
have an impaired capacity to produce ROS.
DiscUssiOn
In the present study we aimed to determine the frequency, 
activation status, maturation stage, and function of neutrophils 
in patients with active VL in Gondar, Northwest Ethiopia. We 
provide evidence that these cells are activated, as shown by the 
increased levels of CD15 and CD63 and decreased levels of 
intracellular arginase, CD62L, and CD10. Whereas CD15 and 
CD62L are not directly related to neutrophil effector functions, 
modulation of their expression levels can be used as a marker 
of activation: CD62L is known to be shed and lost from the cell 
surface of neutrophils following activation (34). CD15 is present 
in the membranes of the primary and secondary granules, and 
is upregulated on neutrophils following activation (34). We have 
A B
C D E
F
FigUre 3 | il-17a, il-27, arginase, myeloperoxidase, and elastase levels in plasma. Plasma was isolated from the blood of healthy controls, VL, and treated 
patients (=VL patients after successful treatment, with initial clinical cure) and the levels of (a) IL-17A and (B) IL-27 were measured by ELISA (20 controls, 22 VL, 
and 20 treated patients). The activity of arginase [(c), 20 controls, 45 VL, and 21 treated patients], the levels of MPO [(D), 25 controls, 20 VL, and 20 treated 
patients], and elastase [(e), 20 controls, 20 VL, and 21 treated patients] were measured by ELISA as described in Section “Materials and Methods.” The neutrophil 
counts (F) were measured using a CELL-DYN 1800, Abbott. Statistical differences were determined using a Kruskal–Wallis test.
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previously shown that CD15 and CD63 are markers of activa-
tion as they are upregulated on a subpopulation of activated 
neutrophils in the blood of healthy controls, as well as the blood 
from HIV seropositive patients (33), VL patients (35, 36), cord 
blood, pregnant women, and in placentae (37). CD63 is found 
in the primary granules of neutrophils and becomes upregulated 
at the surface of neutrophils during degranulation (28, 36, 38). 
Indeed, our results show that arginase, an enzyme also found 
in the primary granules of neutrophils, is significantly lower in 
neutrophils; suggesting that these cells have been activated and 
have degranulated. The increased levels of arginase, myeloper-
oxidase, and elastase we measured in the plasma of VL patients 
further support this conclusion; these enzymes are all contained 
in azurophilic granules that are released following activation 
of neutrophils (38, 39). These enzymes could also exacerbate 
immunopathological processes and therefore disease severity by 
the following mechanisms:
 (i) Arginase: we have previously shown that arginase- 
induced l-arginine depletion results in T cell suppression 
(35, 36, 40, 41) and this mechanism is therefore likely to 
contribute to T cell hyporesponsiveness in VL patients. 
Furthermore, the catabolism of l-arginine by arginase 
results in the production of polyamines that promotes 
parasite growth (32), and might therefore contribute to 
the unrestricted parasite replication in patients with ac-
tive VL.
 (ii)   Myeloperoxidase is a major player in the oxidative killing 
by neutrophils (42) and is therefore likely to contribute to 
parasite killing; however, little is known about the  actual 
effects of MPO on the fate of intracellular Leishmania pa-
rasites. One study showed that myeloperoxidase affects 
parasite survival (43); however, a recent study showed 
that following phagocytosis of Leishmania  parasites by 
neutrophils, the fusion of the myeloperoxidase  containing 
FigUre 4 | neTosis. Neutrophils were isolated by dextran sulfate 
sedimentation from the blood of eight controls, eight VL, and eight treated 
patients (=VL patients after successful treatment, with initial clinical cure). 
Neutrophils were activated with PMA to induce NET release and the 
NET-associated elastase was measured by ELISA as described in Section 
“Materials and Methods.” Statistical differences were determined using a 
Kruskal–Wallis test.
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FigUre 5 | Phagocytosis of particles and L. donovani parasites. Neutrophils were isolated by dextran sulfate sedimentation from the blood of controls 
(13 individuals for E. coli and seven individuals for L. donovani), VL patients (13 individuals for E. coli and nine individuals for L. donovani), and treated patients (=VL 
patients after successful treatment, with initial clinical cure) (=VL patients after successful treatment, 13 individuals for E. coli and seven individuals for L. donovani). 
The percentages of neutrophils (defined as CD15+ cells, Figure 1B) phagocytosing E. coli particles (a), the intensity (MFI = Median Fluorescence Intensity) of E. coli 
particles in neutrophils (B), the percentages of neutrophils (defined as CD15+ cells, Figure 1B) phagocytosing GFP-labeled L. donovani (c), and the intensity of 
GFP-labeled L. donovani parasites in neutrophils (D) were measured by flow cytometry. Statistical differences were determined using a Kruskal–Wallis test.
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granules with phagosomes is blocked, thereby preventing 
potential toxic effects of the content of these granules 
(22). Besides, the increased level of MPO in the plasma 
is not an indication of parasite killing by neutrophils, sin-
ce this needs to take place intracellularly; however, the 
increased MPO level in the plasma is a clear indicator of 
neutrophil activation.
(iii) Elastase was also significantly increased in the plasma of 
VL patients. It has been recently shown that neutrophil 
elastase contributes to parasite killing via crosstalk with 
toll-like receptors (TLRs) on macrophages (44). Since 
Leishmania parasites are not efficiently killed, elastase 
may have been produced in excess as a mechanism of 
feedback control to improve parasite killing. However, we 
have not tested the impact of elastase or MPO released 
by neutrophils on parasite killing. Furthermore, neutro-
phil-derived elastase is a potent mediator of inflamma-
tion and the increased levels we detected in the plasma 
are likely to contribute to the high and sustained syste-
mic inflammation in patients with active VL and might 
A B C
D
FigUre 6 | rOs production in response to pyocyanin. Neutrophils were isolated by dextran sulfate sedimentation from the blood of 17 controls (a), eight VL 
(B), and nine treated patients [=VL patients after successful treatment, with initial clinical cure, (c)] and were incubated in the absence (baseline) or in the presence 
of pyocyanin. The production of ROS was evaluated by measuring the fluorescence (MFI = Median Fluorescence Intensity) resulting from the reaction of ROS with 
the Oxidative Stress Detection buffer. (D) MFI values were obtained by subtracting the values of obtained from the neutrophils (defined as CD15+ cells, Figure 1B) 
incubated without pyocyanin (baseline) from those incubated in the presence of pyocyanin. Statistical differences were determined using a Wilcoxon (a–c) or a 
Kruskal–Wallis test (D).
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be a  potential therapeutic target (45). Of note, we cannot 
exclude that elastase and to a lesser extent myeloperoxi-
dase we detected in the plasma has also been produced 
by macrophages. In addition to their potential role in 
T cell responses and parasite killing, the elevated levels of 
arginase, MPO, and elastase could be considered as bio-
markers of a severe and systemic inflammatory response 
that is at least in part caused by dysregulated neutrophil 
homeostasis and high neutrophil activation.
Our results further confirm that the levels of IL-17A and IL-27 
are elevated in the plasma of patients with active VL (19, 46–48). 
This is line with the increased mixed cytokine and chemokine 
profile characteristic of VL patients (3). In experimental 
models of leishmaniasis, the roles of IL-17A and IL-27 are still 
controversial: IL-17A, in synergy with IFN-γ, has been shown 
to potentiate leishmanicidal activities of infected macrophages 
(49). In contrast, IL-17 can promote progression of CL in sus-
ceptible mice (50). The parasite load in IL-27R−− mice infected 
with Leishmania major was not affected (51), whereas IL-27 has 
been shown to promote Leishmania amazonensis replication in 
macrophages (52). Interestingly, a recent study showed that IL-27 
could mediate susceptibility of mice to L. infantum infections by 
suppressing IL-17 production by neutrophils (53).
A recent study (54) suggested that a subpopulation of low-
density neutrophils (36) express markers of antigen-presenting 
cells. Whereas the authors could not demonstrate that these 
neutrophils can stimulate T cells, it cannot be excluded that these 
cells could act as antigen-presenting cells.
Neutropenia is one of the main clinical characteristics of 
patients with active VL and indeed, here we show drastically 
reduced numbers of neutrophils in VL patients. This supports 
a previous report indicating that neutrophil reserve in the bone 
marrow of VL patients is markedly reduced (55). In addition, 
the expression levels of CD10 are significantly reduced on the 
surface of neutrophils. CD10, also known as Common Acute 
Lymphocytic Leukemia antigen (CALLA), is a neutral endopepti-
dase and is a member of the metalloprotease family; it is expressed 
on B and T cell precursors, and neutrophils. CD10 is important 
in the regulation of chemotactic and inflammatory processes 
involving neutrophils. It is also used as a marker of neutrophil 
maturity as it is only expressed on immature band neutrophils 
(34). Furthermore, newly released neutrophils express much 
less CD10 (56). Our results show a dramatic reduction in the 
9Yizengaw et al. Neutrophils during Human Visceral Leishmaniasis
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 517
expression levels of CD10 on neutrophils. It is also possible that 
the decreased levels of CD10 might be a sign of activation, and 
indeed, this has been previously described for low-density granu-
locytes from SLE patients (57) as well as following in vivo inflam-
matory challenges (58). Since CD10 is a major metalloproteinase 
that can regulate levels of biologically active peptides that initiate 
inflammation, it is possible that CD10 is downregulated on the 
surface of neutrophils in VL patients in an attempt to control the 
severe inflammatory response.
The immaturity of neutrophils in VL patients might also 
explain why these cells, despite the fact that they can be activated, 
display impaired effector functions. Indeed, our results show that 
neutrophils from VL patients cannot produce ROS efficiently, 
both following activation with pyocyanin and L. donovani. This 
might not only contribute to the lack of parasite killing, but also 
explain the increased incidence of bacterial infections in these 
patients (25). Furthermore, our results show that neutrophils 
display an impaired capacity to phagocytose E. coli particles, 
further explaining the high incidence of secondary infection in 
VL patients. In contrast, neutrophils from VL patients had a simi-
lar ability to phagocytose L. donovani parasites as compared to 
healthy controls. This could facilitate the survival and propagation 
of L. donovani: phagocytosis of infected apoptotic neutrophils by 
macrophages can result in a “silent” entry, without activation 
and therefore avoid killing of the parasites by the macrophages, 
thereby promoting uncontrolled parasite replication. It has also 
been shown that Leishmania-infected macrophages have a pro-
longed half-life, this could allow more time for the monocytes to 
migrate to the site of infection and uptake of infected apoptotic 
neutrophils (59, 60).
Phagocytosis of Leishmania parasites by neutrophils has been 
shown to be dependent on complement receptor 3 (CR3) and 
TLR2, suggesting both opsonin-dependent and opsonin-inde-
pendent mechanisms are involved (61, 62). Lipophosphoglycan 
(LPG) also plays important roles in the early interaction of 
Leishmania parasites with phagocytic cells: LPG has been shown 
to inhibit activation of protein kinase C (PKC), a key macrophage 
signaling protein, and help in the parasite’s silent entry (63).
Importantly, our results also show that the majority of param-
eters we analyzed such as the activation status of neutrophils, 
the levels of arginase in plasma, the total neutrophil counts, the 
number of band neutrophils, NETosis, ROS production, and 
phagocytosis of E. coli particles were not restored after success-
ful treatment of VL. These results show that despite the “clinical 
A B C
D
FigUre 7 | rOs production in response to L. donovani parasites. Neutrophils were isolated by dextran sulfate sedimentation from the blood of seven controls 
(a), seven VL (B), and seven treated patients [=VL patients after successful treatment, with initial clinical cure, (c)] and were incubated in the absence (baseline) or 
in the presence of L. donovani parasites. The production of ROS was evaluated by measuring the fluorescence (MFI = Median Fluorescence Intensity) resulting from 
the reaction of ROS with the Oxidative Stress Detection buffer. (D) MFI values were obtained by subtracting the values of obtained from the neutrophils (defined as 
CD15+ cells, Figure 1B) incubated without L. donovani (baseline) from those incubated in the presence of L. donovani parasites. Statistical differences were 
determined using a Wilcoxon (a–c) or a Kruskal–Wallis test (D).
10
Yizengaw et al. Neutrophils during Human Visceral Leishmaniasis
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 517
reFerences
1. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis 
worldwide and global estimates of its incidence. PLoS One (2012) 7:e35671. 
doi:10.1371/journal.pone.0035671 
2. Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden 
attributable to leishmaniasis. PLoS Negl Trop Dis (2008) 2:e313. doi:10.1371/
journal.pntd.0000313 
3. Nylen S, Sacks D. Interleukin-10 and the pathogenesis of human visceral 
leishmaniasis. Trends Immunol (2007) 28:378–84. doi:10.1016/j.it.2007.07.004 
4. Goto H, Prianti MG. Immunoactivation and immunopathogeny during 
active visceral leishmaniasis. Rev Inst Med Trop Sao Paulo (2009) 51:241–6. 
doi:10.1590/S0036-46652009000500002 
5. Gidwani K, Jones S, Kumar R, Boelaert M, Sundar S. Interferon-gamma 
release assay (modified QuantiFERON) as a potential marker of infection for 
Leishmania donovani, a proof of concept study. PLoS Negl Trop Dis (2011) 
5:e1042. doi:10.1371/journal.pntd.0001042 
6. Singh OP, Gidwani K, Kumar R, Nylen S, Jones SL, Boelaert M, et  al. 
Reassessment of immune correlates in human visceral leishmaniasis as 
defined by cytokine release in whole blood. Clin Vaccine Immunol (2012) 
19:961–6. doi:10.1128/CVI.00143-12 
7. Adem E, Tajebe F, Getahun M, Kiflie A, Diro E, Hailu A, et  al. Successful 
treatment of human visceral leishmaniasis restores antigen-specific IFN-
gamma, but not IL-10 production. PLoS Negl Trop Dis (2016) 10:e0004468. 
doi:10.1371/journal.pntd.0004468 
8. Perez-Mazliah D, Langhorne J. CD4 T-cell subsets in malaria: TH1/TH2 
revisited. Front Immunol (2014) 5:671. doi:10.3389/fimmu.2014.00671
9. Cohen J, Vincent JL, Adhikari NK, Machado FR, Angus DC, Calandra T, et al. 
Sepsis: a roadmap for future research. Lancet Infect Dis (2015) 15:581–614. 
doi:10.1016/S1473-3099(15)70112-X 
10. Jaillon S, Galdiero MR, Del Prete D, Cassatella MA, Garlanda C, Mantovani A. 
Neutrophils in innate and adaptive immunity. Semin Immunopathol (2013) 
35:377–94. doi:10.1007/s00281-013-0374-8 
11. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the 
activation and regulation of innate and adaptive immunity. Nat Rev Immunol 
(2011) 11:519–31. doi:10.1038/nri3024 
12. Kruger P, Saffarzadeh M, Weber AN, Rieber N, Radsak M, von Bernuth H, 
et  al. Neutrophils: between host defence, immune modulation, and tissue 
injury. PLoS Pathog (2015) 11:e1004651. doi:10.1371/journal.ppat.1004651 
13. Conceicao J, Davis R, Carneiro PP, Giudice A, Muniz AC, Wilson ME, et al. 
Characterization of neutrophil function in human cutaneous leishmaniasis 
caused by Leishmania braziliensis. PLoS Negl Trop Dis (2016) 10:e0004715. 
doi:10.1371/journal.pntd.0004715 
14. Morgado FN, Nascimento MT, Saraiva EM, de Oliveira-Ribeiro C, Madeira 
Mde F, da Costa-Santos M, et al. Are neutrophil extracellular traps playing 
a role in the parasite control in active American tegumentary leishmaniasis 
lesions? PLoS One (2015) 10:e0133063. doi:10.1371/journal.pone.0133063 
15. Safaiyan S, Bolhassani A, Nylen S, Akuffo H, Rafati S. Contribution of human 
neutrophils in the development of protective immune response during 
in  vitro Leishmania major infection. Parasite Immunol (2011) 33:609–20. 
doi:10.1111/j.1365-3024.2011.01321.x 
16. Carlsen ED, Liang Y, Shelite TR, Walker DH, Melby PC, Soong L. Permissive 
and protective roles for neutrophils in leishmaniasis. Clin Exp Immunol (2015) 
182(2):109–18. doi:10.1111/cei.12674 
17. Hurrell BP, Regli IB, Tacchini-Cottier F. Different Leishmania species 
drive distinct neutrophil functions. Trends Parasitol (2016) 32:392–401. 
doi:10.1016/j.pt.2016.02.003 
18. Costa DL, Rocha RL, Carvalho RM, Lima-Neto AS, Harhay MO, Costa CH, 
et al. Serum cytokines associated with severity and complications of kala-azar. 
Pathog Glob Health (2013) 107:78–87. doi:10.1179/2047773213Y.0000000078 
cure,” the immune system of these patients is still impaired at 
the time they are released from hospital. This is in line with our 
previous study that showed that the capacity of whole blood 
cells to respond to antigenic and polyclonal stimulation with 
IFN-γ production was not restored in treated patients (7). This 
is of relevance in Ethiopia, where a new treatment is used, a 
combination of PM and SSG, which reduced the hospitalization 
of VL patients from 28 to 17  days. However, this combination 
treatment has been associated with increased rates of relapse of 
VL in Sudan (64). This will also be of particular relevance for VL 
patients coinfected with HIV that have a significantly higher risk 
of relapse (65) following treatment.
Whereas the role of neutrophils in human VL has been poorly 
characterized, the role of neutrophils in CL has been better 
defined, primarily in experimental model of CL. For example, 
neutropenia induced transiently by depletion of neutrophils 
with monoclonal antibodies or in genetically modified mice 
without mature neutrophils (Genista mice) results in uncon-
trolled parasites replication following infections with Leishmania 
mexicana (66). NETosis has been shown to be induced in vitro 
by L. amazonensis, L. major, and L. mexicana (17, 66, 67), with 
killing of L. amazonensis (67), but not L. mexicana (66). ROS 
production has also been shown to differ depending on the strain 
of parasites: production of ROS was significantly higher following 
infection of neutrophils with Leishmania braziliensis as compared 
to L. amazonensis (68). Altogether, the results obtained in both 
human and experimental leishmaniasis show that the neutrophil 
effector functions are affected differentially by different species of 
Leishmania parasites.
In conclusion, our results show that patients with active 
VL in Ethiopia are neutropenic, their circulating neutrophils 
are highly activated, but have impaired effector functions and 
an increased frequency of immature neutrophils. We propose 
that dysfunctional neutrophils play a key role in the severe and 
systemic inflammatory response characteristic of these patients 
and therefore contribute to disease severity. More work into 
the role of inflammation in VL patients and the possible use of 
anti-inflammatory drugs in combination with anti-leishmanial 
therapy is warranted.
aUThOr cOnTriBUTiOns
Conceived and designed the experiments: YT, IM, and PK. 
Performed the experiments: EY, MG, FT, EC, EA, GM, GA, VY, 
ML, AY, RM, BM, IM, YT, and PK. Analyzed the data: EY, MG, 
FT, EC, AH, ED, ZS, MMo, MMu, IM, YT, and PK. Wrote the 
paper: EY, MG, FT, EC, MMo, MMu, YT, IM, and PK.
acKnOWleDgMenTs
We thank Tadele Mulaw, Saba Atnafu, Aschalew Tamiru, 
Zemenay Mulugeta, Tigist Mekonen, Yohannes Sinku, and Eden 
G/Hiwot from the University of Gondar for their invaluable help 
and enthusiastic cooperation in this study. The authors would like 
to also thank DNDi for their in-kind support in funding the staff 
of the Gondar University Leishmaniasis Research and Treatment 
Centre. YT is supported by a fellowship from the Wellcome Trust 
(104027/B/14/Z).
11
Yizengaw et al. Neutrophils during Human Visceral Leishmaniasis
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 517
19. Santos-Oliveira JR, Regis EG, Giacoia-Gripp CB, Valverde JG, Alexandrino-
de-Oliveira P, Lindoso JA, et  al. Microbial translocation induces an 
intense proinflammatory response in patients with visceral leishmaniasis 
and HIV type 1 coinfection. J Infect Dis (2013) 208:57–66. doi:10.1093/ 
infdis/jit135 
20. Pearson RD, Steigbigel RT. Phagocytosis and killing of the protozoan 
Leishmania donovani by human polymorphonuclear leukocytes. J Immunol 
(1981) 127:1438–43. 
21. Remaley AT, Kuhns DB, Basford RE, Glew RH, Kaplan SS. Leishmanial phos-
phatase blocks neutrophil O-2 production. J Biol Chem (1984) 259:11173–5. 
22. Mollinedo F, Janssen H, de la Iglesia-Vicente J, Villa-Pulgarin JA, Calafat 
J. Selective fusion of azurophilic granules with Leishmania-containing phago-
somes in human neutrophils. J Biol Chem (2010) 285:34528–36. doi:10.1074/
jbc.M110.125302 
23. Gabriel C, McMaster WR, Girard D, Descoteaux A. Leishmania donovani 
promastigotes evade the antimicrobial activity of neutrophil extracellular 
traps. J Immunol (2010) 185:4319–27. doi:10.4049/jimmunol.1000893 
24. Guimaraes-Costa AB, DeSouza-Vieira TS, Paletta-Silva R, Freitas-Mesquita 
AL, Meyer-Fernandes JR, Saraiva EM. 3’-nucleotidase/nuclease activity allows 
Leishmania parasites to escape killing by neutrophil extracellular traps. Infect 
Immun (2014) 82:1732–40. doi:10.1128/IAI.01232-13 
25. Endris M, Takele Y, Woldeyohannes D, Tiruneh M, Mohammed R, Moges F, 
et  al. Bacterial sepsis in patients with visceral leishmaniasis in Northwest 
Ethiopia. Biomed Res Int (2014) 2014:361058. doi:10.1155/2014/361058 
26. Badaro R, Nascimento C, Carvalho JS, Badaro F, Russo D, Ho JL, et  al. 
Recombinant human granulocyte-macrophage colony-stimulating factor 
reverses neutropenia and reduces secondary infections in visceral leishmani-
asis. J Infect Dis (1994) 170:413–8. doi:10.1093/infdis/170.2.413 
27. Chulay JD, Bryceson AD. Quantitation of amastigotes of Leishmania donovani 
in smears of splenic aspirates from patients with visceral leishmaniasis. Am 
J Trop Med Hyg (1983) 32:475–9. 
28. Cloke T, Munder M, Taylor GP, Müller I, Kropf P. Characterization of a novel 
population of low-density granulocytes associated with disease severity in 
HIV seropositive patients. PLoS One (2012) 7:e48939. doi:10.1371/journal.
pone.0048939 
29. Van der Auwera G, Maes I, De Doncker S, Ravel C, Cnops L, Van Esbroeck 
M, et al. Heat-shock protein 70 gene sequencing for Leishmania species typing 
in European tropical infectious disease clinics. Euro Surveill (2013) 18:20543. 
doi:10.2807/1560-7917.ES2013.18.30.20543 
30. Kropf P, Baud D, Marshall SE, Munder M, Mosley A, Fuentes JM, 
et  al. Arginase activity mediates reversible T cell hyporesponsiveness 
in human pregnancy. Eur J Immunol (2007) 37:935–45. doi:10.1002/ 
eji.200636542 
31. Choi BS, Martinez-Falero IC, Corset C, Munder M, Modolell M, Muller  I, 
et  al. Differential impact of l-arginine deprivation on the activation and 
effector functions of T cells and macrophages. J Leukoc Biol (2009) 85:268–77. 
doi:10.1189/jlb.0508310 
32. Kropf P, Fuentes JM, Fahnrich E, Arpa L, Herath S, Weber V, et al. Arginase 
and polyamine synthesis are key factors in the regulation of experimental 
leishmaniasis in vivo. FASEB J (2005) 19:1000–2. doi:10.1096/fj.04-3416fje
33. Cloke T, Munder M, Bergin P, Herath S, Modolell M, Taylor G, et al. Phenotypic 
alteration of neutrophils in the blood of HIV seropositive patients. PLoS One 
(2013) 8:e72034. doi:10.1371/journal.pone.0072034 
34. Elghetany MT. Surface antigen changes during normal neutrophilic develop-
ment: a critical review. Blood Cells Mol Dis (2002) 28:260–74. doi:10.1006/
bcmd.2002.0513 
35. Takele Y, Abebe T, Weldegebreal T, Hailu A, Hailu W, Hurissa Z, et al. Arginase 
activity in the blood of patients with visceral leishmaniasis and HIV infection. 
PLoS Negl Trop Dis (2013) 7:e1977. doi:10.1371/journal.pntd.0001977 
36. Abebe T, Takele T, Weldegebreal T, Cloke T, Closs E, Corset C, et al. Arginase: 
a marker of disease status in patients with visceral leishmaniasis. PLoS Negl 
Trop Dis (2013) 7:e2134. doi:10.1371/journal.pntd.0002134
37. Ssemaganda A, Kindinger L, Bergin P, Nielsen L, Mpendo J, Ssetaala A, et al. 
Characterization of neutrophil subsets in healthy human pregnancies. PLoS 
One (2014) 9:e85696. doi:10.1371/journal.pone.0085696 
38. Kuijpers TW, Tool AT, van der Schoot CE, Ginsel LA, Onderwater JJ, Roos D, 
et al. Membrane surface antigen expression on neutrophils: a reappraisal of 
the use of surface markers for neutrophil activation. Blood (1991) 78:1105–11. 
39. Martin-Martin B, Nabokina SM, Blasi J, Lazo PA, Mollinedo F. Involvement 
of SNAP-23 and syntaxin 6 in human neutrophil exocytosis. Blood (2000) 
96:2574–83. 
40. Modolell M, Choi B-S, Ryan RO, Hancock M, Titus RG, Abebe T, et al. Local 
suppression of T cell responses by arginase-induced l-arginine depletion in 
nonhealing leishmaniasis. PLoS Negl Trop Dis (2009) 14:e480. doi:10.1371/
journal.pntd.0000480 
41. Munder M. Arginase: an emerging key player in the mammalian immune sys-
tem. Br J Pharmacol (2009) 158:638–51. doi:10.1111/j.1476-5381.2009.00291.x 
42. Klebanoff SJ, Kettle AJ, Rosen H, Winterbourn CC, Nauseef WM. 
Myeloperoxidase: a front-line defender against phagocytosed microorgan-
isms. J Leukoc Biol (2013) 93:185–98. doi:10.1189/jlb.0712349 
43. Locksley RM, Nelson CS, Fankhauser JE, Klebanoff SJ. Loss of granule 
myeloperoxidase during in vitro culture of human monocytes correlates with 
decay in antiprotozoa activity. Am J Trop Med Hyg (1987) 36:541–8. 
44. Faria MS, Calegari-Silva TC, de Carvalho Vivarini A, Mottram JC, Lopes UG, 
Lima AP. Role of protein kinase R in the killing of Leishmania major by 
macrophages in response to neutrophil elastase and TLR4 via TNFalpha and 
IFNbeta. FASEB J (2014) 28:3050–63. doi:10.1096/fj.13-245126 
45. Henriksen PA. The potential of neutrophil elastase inhibitors as 
 anti-inflammatory therapies. Curr Opin Hematol (2014) 21:23–8. doi:10.1097/
MOH.0000000000000001 
46. Dos Santos PL, de Oliveira FA, Santos ML, Cunha LC, Lino MT, de Oliveira 
MF, et al. The severity of visceral leishmaniasis correlates with elevated levels 
of serum IL-6, IL-27 and sCD14. PLoS Negl Trop Dis (2016) 10:e0004375. 
doi:10.1371/journal.pntd.0004375 
47. Ansari NA, Kumar R, Gautam S, Nylen S, Singh OP, Sundar S, et al. IL-27 and 
IL-21 are associated with T cell IL-10 responses in human visceral leishmani-
asis. J Immunol (2011) 186:3977–85. doi:10.4049/jimmunol.1003588 
48. van den Bogaart E, Talha AB, Straetemans M, Mens PF, Adams ER, 
Grobusch MP, et  al. Cytokine profiles amongst Sudanese patients with vis-
ceral leishmaniasis and malaria co-infections. BMC Immunol (2014) 15:16. 
doi:10.1186/1471-2172-15-16 
49. Banerjee A, Bhattacharya P, Joshi AB, Ismail N, Dey R, Nakhasi HL. Role 
of pro-inflammatory cytokine IL-17 in Leishmania pathogenesis and in pro-
tective immunity by Leishmania vaccines. Cell Immunol (2016). doi:10.1016/ 
j.cellimm.2016.07.004 
50. Lopez Kostka S, Dinges S, Griewank K, Iwakura Y, Udey MC, von Stebut E. 
IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice. 
J Immunol (2009) 182:3039–46. doi:10.4049/jimmunol.0713598 
51. Anderson CF, Stumhofer JS, Hunter CA, Sacks D. IL-27 regulates IL-10 and 
IL-17 from CD4+ cells in nonhealing Leishmania major infection. J Immunol 
(2009) 183:4619–27. doi:10.4049/jimmunol.0804024 
52. Barreto-de-Souza V, Ferreira PL, Vivarini Ade C, Calegari-Silva T, Soares DC, 
Regis EG, et  al. IL-27 enhances Leishmania amazonensis infection via 
ds-RNA dependent kinase (PKR) and IL-10 signaling. Immunobiology (2015) 
220:437–44. doi:10.1016/j.imbio.2014.11.006 
53. Quirino GF, Nascimento MS, Davoli-Ferreira M, Sacramento LA, Lima MH, 
Almeida RP, et al. Interleukin-27 (IL-27) mediates susceptibility to visceral 
leishmaniasis by suppressing the IL-17-neutrophil response. Infect Immun 
(2016) 84:2289–98. doi:10.1128/IAI.00283-16 
54. Sharma S, Davis RE, Srivastva S, Nylen S, Sundar S, Wilson ME. A subset 
of neutrophils expressing markers of antigen-presenting cells in human 
visceral leishmaniasis. J Infect Dis (2016) 214(10):1531–8. doi:10.1093/ 
infdis/jiw394 
55. Musumeci S, D’Agata A, Schiliro G, Fischer A. Leukokinetic studies in 
Mediterranean kala azar. Acta Trop (1978) 35:183–93. 
56. Zarco MA, Ribera JM, Urbano-Ispizua A, Filella X, Arriols R, Martinez C, 
et al. Phenotypic changes in neutrophil granulocytes of healthy donors after 
G-CSF administration. Haematologica (1999) 84:874–8. 
57. Denny MF, Yalavarthi S, Zhao W, Thacker SG, Anderson M, Sandy AR, et al. 
A distinct subset of proinflammatory neutrophils isolated from patients with 
systemic lupus erythematosus induces vascular damage and synthesizes type I 
IFNs. J Immunol (2010) 184:3284–97. doi:10.4049/jimmunol.0902199 
58. Kaneko T, Stearns-Kurosawa DJ, Taylor F Jr, Twigg M, Osaki K, Kinasewitz GT, 
et  al. Reduced neutrophil CD10 expression in nonhuman primates and 
humans after in vivo challenge with E. coli or lipopolysaccharide. Shock (2003) 
20:130–7. doi:10.1097/01.shk.0000068326.68761.34 
12
Yizengaw et al. Neutrophils during Human Visceral Leishmaniasis
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 517
59. Laskay T, van Zandbergen G, Solbach W. Neutrophil granulocytes – Trojan 
horses for Leishmania major and other intracellular microbes? Trends 
Microbiol (2003) 11:210–4. doi:10.1016/S0966-842X(03)00075-1 
60. van Zandbergen G, Klinger M, Mueller A, Dannenberg S, Gebert A, 
Solbach  W, et  al. Cutting edge: neutrophil granulocyte serves as a vector 
for Leishmania entry into macrophages. J Immunol (2004) 173:6521–5. 
doi:10.4049/jimmunol.173.11.6521 
61. Laufs H, Müller K, Fleischer J, Reiling N, Jahnke N, Jensenius JC, et  al. 
Intracellular survival of Leishmania major in neutrophil granulocytes after 
uptake in the absence of heat-labile serum factors. Infect Immun (2002) 
70:826–35. doi:10.1128/IAI.70.2.826-835.2002 
62. Tavares NM, Araujo-Santos T, Afonso L, Nogueira PM, Lopes UG, Soares RP, 
et  al. Understanding the mechanisms controlling Leishmania amazonensis 
infection in vitro: the role of LTB4 derived from human neutrophils. J Infect 
Dis (2014) 210:656–66. doi:10.1093/infdis/jiu158 
63. Atayde VD, Hassani K, da Silva Lira Filho A, Borges AR, Adhikari A, 
Martel C, et al. Leishmania exosomes and other virulence factors: impact on 
innate immune response and macrophage functions. Cell Immunol (2016). 
doi:10.1016/j.cellimm.2016.07.013 
64. Gorski S, Collin SM, Ritmeijer K, Keus K, Gatluak F, Mueller M, et al. Visceral 
leishmaniasis relapse in Southern Sudan (1999-2007): a retrospective study of 
risk factors and trends. PLoS Negl Trop Dis (2010) 4:e705. doi:10.1371/journal.
pntd.0000705 
65. Diro E, Lynen L, Mohammed R, Boelaert M, Hailu A, van Griensven J. High 
parasitological failure rate of visceral leishmaniasis to sodium stibogluconate 
among HIV co-infected adults in Ethiopia. PLoS Negl Trop Dis (2014) 8:e2875. 
doi:10.1371/journal.pntd.0002875 
66. Hurrell BP, Schuster S, Grun E, Coutaz M, Williams RA, Held W, et al. Rapid 
sequestration of Leishmania mexicana by neutrophils contributes to the 
development of chronic lesion. PLoS Pathog (2015) 11:e1004929. doi:10.1371/
journal.ppat.1004929 
67. Guimaraes-Costa AB, Nascimento MT, Froment GS, Soares RP, Morgado FN, 
Conceicao-Silva F, et al. Leishmania amazonensis promastigotes induce and 
are killed by neutrophil extracellular traps. Proc Natl Acad Sci U S A (2009) 
106:6748–53. doi:10.1073/pnas.0900226106 
68. Carlsen ED, Jie Z, Liang Y, Henard CA, Hay C, Sun J, et  al. Interactions 
between neutrophils and Leishmania braziliensis amastigotes facilitate 
cell activation and parasite clearance. J Innate Immun (2015) 7:354–63. 
doi:10.1159/000373923 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Yizengaw, Getahun, Tajebe, Cruz Cervera, Adem, Mesfin, 
Hailu, Van der Auwera, Yardley , Lemma, Skhedy , Diro, Yeshanew , Melkamu, 
Mengesha, Modolell, Munder, Müller , Takele and Kropf . This is an open-access 
article distributed under the terms of the Creative Commons Attribution License 
(CC BY). The use, distribution or reproduction in other forums is permitted, 
provided the original author(s) or licensor are credited and that the original 
publication in this journal is cited, in accordance with accepted academic prac-
tice. No use, distribution or reproduction is permitted which does not comply 
with these terms.
